MDElliottMD: Add scope="col" to the data-table column headers for screen-reader association (ADA audit M5; designer-claude 2026-05-22)

2026-05-22T16:53:08Z

Add scope="col" to the data-table column headers for screen-reader association (ADA audit M5; designer-claude 2026-05-22)

← Older revision		Revision as of 16:53, 22 May 2026
Line 8:		Line 8:
	{\| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;"		{\| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;"
	\|+ style="white-space:nowrap; text-align:left;" \| near-complete CYP2D6 substrate table (click to expand)		\|+ style="white-space:nowrap; text-align:left;" \| near-complete CYP2D6 substrate table (click to expand)
	! Substrate !! Therapeutic class !! CYP2D6 contribution !! Clinical notes		! scope="col" \| Substrate !! scope="col" \| Therapeutic class !! scope="col" \| CYP2D6 contribution !! scope="col" \| Clinical notes
	\|-		\|-
	\| [[Amitriptyline]] \|\| Tricyclic antidepressant \|\| major \|\| CPIC TCA guideline dose adjustment in CYP2D6 PM/UM.		\| [[Amitriptyline]] \|\| Tricyclic antidepressant \|\| major \|\| CPIC TCA guideline dose adjustment in CYP2D6 PM/UM.
Line 107:		Line 107:

	{\| class="wikitable"		{\| class="wikitable"
	! Phenotype !! Abbreviation !! Activity score !! Frequency (varies by ancestry)		! scope="col" \| Phenotype !! scope="col" \| Abbreviation !! scope="col" \| Activity score !! scope="col" \| Frequency (varies by ancestry)
	\|-		\|-
	\| [[Phenotype:CYP2D6 poor metabolizer\|Poor metabolizer]] \|\| PM \|\| 0 \|\| 5–10% (European), 1–2% (East Asian), 3–8% (African)		\| [[Phenotype:CYP2D6 poor metabolizer\|Poor metabolizer]] \|\| PM \|\| 0 \|\| 5–10% (European), 1–2% (East Asian), 3–8% (African)

MDElliottMD: MDElliottMD moved page Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2D6 to Enzyme:CYP2D6: Migrate enzyme entity pages from Pharmacogenomics sandbox to the new Enzyme: namespace

2026-05-22T02:55:06Z

MDElliottMD moved page Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2D6 to Enzyme:CYP2D6: Migrate enzyme entity pages from Pharmacogenomics sandbox to the new Enzyme: namespace

← Older revision		Revision as of 02:55, 22 May 2026
(No difference)

MDElliottMD: Consolidate enzyme entity page to canonical Pharmacopedia: sandbox location per Mark 2026-05-19. Full retrofitted version: history-first spine, collapsible-sortable substrate table, comprehensive-tables pointer, all PMIDs NCBI-eutils-verified, zero em-dashes. For CYP2D6/CYP3A4/CYP2C19 this replaces the earlier pre-retrofit draft with the full version; for the other 8 enzymes this is the first save at the canonical location. Resolves a cross-session sandbox-location duplication: the User:MDEll...

2026-05-19T22:39:06Z

Consolidate enzyme entity page to canonical Pharmacopedia: sandbox location per Mark 2026-05-19. Full retrofitted version: history-first spine, collapsible-sortable substrate table, comprehensive-tables pointer, all PMIDs NCBI-eutils-verified, zero em-dashes. For CYP2D6/CYP3A4/CYP2C19 this replaces the earlier pre-retrofit draft with the full version; for the other 8 enzymes this is the first save at the canonical location. Resolves a cross-session sandbox-location duplication: the User:MDEll...

Show changes

MDElliottMD: Pharmacogenomics entity page prototype: CYP2D6. First of 10 canonical enzyme pages (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, UGT1A1, TPMT) to be built in Phase 1. Sandboxed at Pharmacopedia:Pharmacogenomics sandbox/ until interface-claude registers the Enzyme: custom namespace; will move to Enzyme:CYP2D6 thereafter. Cites Crews 2021 CPIC opioid guideline (PMID 33387367) + Caudle 2020 CPIC/DPWG CYP2D6 harmonization (PMID 31647186). 0 em-dashes; 16 en-dashes (all in nume...

2026-05-19T05:29:18Z

Pharmacogenomics entity page prototype: CYP2D6. First of 10 canonical enzyme pages (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, UGT1A1, TPMT) to be built in Phase 1. Sandboxed at Pharmacopedia:Pharmacogenomics sandbox/ until interface-claude registers the Enzyme: custom namespace; will move to Enzyme:CYP2D6 thereafter. Cites Crews 2021 CPIC opioid guideline (PMID 33387367) + Caudle 2020 CPIC/DPWG CYP2D6 harmonization (PMID 31647186). 0 em-dashes; 16 en-dashes (all in nume...

New page

'''CYP2D6''' (cytochrome P450 2D6) is a hepatic drug-metabolizing enzyme of the cytochrome P450 superfamily. It is encoded by the ''CYP2D6'' gene on chromosome 22q13.2 and accounts for roughly 2–4% of total hepatic CYP protein, yet metabolizes an outsized fraction of the medicines in clinical use (estimates range from 20 to 25% of all prescribed drugs touch CYP2D6 in some way). It is the most extensively polymorphic of the human CYP enzymes, with more than 100 named star-allele variants ranging from complete loss of function to gain-of-function gene duplications. Because of this polymorphism and the steepness of the dose-response relationship for several CYP2D6-dependent medicines, CYP2D6 is the most clinically consequential single pharmacogenomic locus in routine prescribing.<ref name="cpic-opioid-2021">Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. ''Clin Pharmacol Ther''. 2021 Oct;110(4):888-896. PMID: 33387367.</ref>

== Function and substrate spectrum ==
CYP2D6 catalyzes O-dealkylation, N-dealkylation, hydroxylation, and oxidation of a wide range of lipophilic substrates that share a basic nitrogen 5–7 Å from an aromatic carbon. The enzyme is uninducible by classical pharmacological inducers (rifampin, carbamazepine, phenobarbital), which distinguishes it from CYP3A4 and CYP1A2 and means that CYP2D6 inhibition cannot be overcome by attempting to upregulate the enzyme.

Substrate classes of clinical importance include:

* '''Opioid prodrug activators''': [[Codeine|codeine]] → [[Morphine|morphine]], [[Tramadol|tramadol]] → O-desmethyltramadol (M1), [[Hydrocodone|hydrocodone]] → hydromorphone. Loss-of-function CYP2D6 reduces or abolishes analgesia; gain-of-function increases morphine exposure and respiratory-depression risk.<ref name="cpic-opioid-2021" />
* '''Antidepressants''': all tricyclics ([[Amitriptyline|amitriptyline]], [[Nortriptyline|nortriptyline]], [[Imipramine|imipramine]], [[Desipramine|desipramine]], [[Clomipramine|clomipramine]]) and several SSRIs ([[Fluoxetine|fluoxetine]] is itself a substrate as well as an inhibitor; [[Paroxetine|paroxetine]] is a substrate as well as a mechanism-based inhibitor; [[Venlafaxine|venlafaxine]], [[Vortioxetine|vortioxetine]]). CPIC publishes phenotype-specific dosing guidance for the tricyclics and several SSRIs.
* '''Antipsychotics''': [[Risperidone|risperidone]], [[Aripiprazole|aripiprazole]], [[Haloperidol|haloperidol]], [[Iloperidone|iloperidone]], [[Brexpiprazole|brexpiprazole]], [[Pimozide|pimozide]]. Pimozide carries an FDA boxed warning regarding CYP2D6 genotype.
* '''β-blockers''': [[Metoprolol|metoprolol]] (substantially), [[Carvedilol|carvedilol]], [[Propranolol|propranolol]] (partial). CYP2D6 polymorphism contributes to wide inter-individual variability in β-blockade.
* '''Antiarrhythmics''': [[Flecainide|flecainide]], [[Mexiletine|mexiletine]], propafenone.
* '''Tamoxifen''': metabolized to endoxifen, the clinically active metabolite; CYP2D6 phenotype influences tamoxifen efficacy in breast cancer treatment, though the magnitude of effect in modern adjuvant regimens has been debated.
* '''Others''': atomoxetine (a CPIC Level A example for ADHD prescribing), dextromethorphan, perhexiline (catastrophic hepatotoxicity in poor metabolizers).

== Phenotype categories and activity-score system ==
CYP2D6 phenotype is assigned by summing the activity-score values of an individual's two ''CYP2D6'' alleles. The harmonized 2019 consensus assigns each allele a value from 0 (no function) to 2.0 (increased function for some star alleles; alleles in tandem duplications add proportionally).<ref name="caudle2020">Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. ''Clin Transl Sci''. 2020 Jan;13(1):116-124. PMID: 31647186.</ref>

{| class="wikitable"
! Phenotype !! Abbreviation !! Activity score !! Frequency (varies by ancestry)
|-
| [[Phenotype:CYP2D6 poor metabolizer|Poor metabolizer]] || PM || 0 || 5–10% (European), 1–2% (East Asian), 3–8% (African)
|-
| [[Phenotype:CYP2D6 intermediate metabolizer|Intermediate metabolizer]] || IM || >0 to ≤1.25 || 10–17% (European), 30–50% (East Asian), 20–35% (African)
|-
| [[Phenotype:CYP2D6 normal metabolizer|Normal metabolizer]] || NM || >1.25 to ≤2.25 || 65–80% (European), 45–65% (East Asian), 50–70% (African)
|-
| [[Phenotype:CYP2D6 ultrarapid metabolizer|Ultrarapid metabolizer]] || UM || >2.25 || 1–5% (European), <1% (East Asian), 1–10% (African), up to 28% (Ethiopian, some North African and Middle Eastern populations)
|}

The activity-score scheme superseded the older categorical "extensive metabolizer" (EM, now called NM) terminology in the 2019 harmonization between CPIC and the Dutch Pharmacogenetics Working Group (DPWG).<ref name="caudle2020" /> The relabeling reflects that "extensive" was being read by clinicians as "above-normal" when it actually meant "typical".

== Major star alleles ==
The full catalog of named alleles is maintained at PharmVar (formerly the Human CYP Allele Nomenclature Committee). Clinically the most-encountered are:

* '''*1''', reference, fully functional (activity 1.0)
* '''*2''', fully functional or near-normal (activity 1.0)
* '''*3''', frameshift, no function (activity 0)
* '''*4''', splice variant, the most common no-function allele in European-ancestry populations (activity 0)
* '''*5''', whole-gene deletion (activity 0)
* '''*6''', frameshift, no function (activity 0)
* '''*10''', decreased function (activity 0.25); the most common decreased-function allele in East Asian populations
* '''*17''', decreased function (activity 0.5); most common in African-ancestry populations
* '''*41''', decreased function (activity 0.25)
* '''*xN''', gene duplication of any allele; an *1xN duplication adds 1.0 per extra copy of *1, producing UM phenotypes

== Inhibitors ==
CYP2D6 inhibition by a co-prescribed medicine produces a "'''phenocopy'''" of CYP2D6 deficiency: an individual with the genotype of a normal metabolizer behaves as an intermediate or poor metabolizer for as long as the inhibitor is present. The strength and kinetic class of inhibition determine the magnitude and duration of the effect.

Strong reversible-competitive inhibitors include [[Fluoxetine|fluoxetine]] (plus its long-half-life metabolite norfluoxetine), [[Bupropion|bupropion]], quinidine. Strong mechanism-based inhibitors include [[Paroxetine|paroxetine]] (mechanism-based component contributes to the slow recovery of CYP2D6 activity after discontinuation) and terbinafine (covalent inactivation). Moderate inhibitors include [[Duloxetine|duloxetine]], [[Sertraline|sertraline]] (only at higher doses), [[Cinacalcet|cinacalcet]].

The clinical relevance of CYP2D6 inhibition is greatest for substrates whose elimination depends predominantly on CYP2D6 (no redundant pathway) and whose dose-response sits on a steep part of the curve. [[Codeine|Codeine]] and [[Tramadol|tramadol]] are the textbook cases; [[Metoprolol|metoprolol]] and [[Tamoxifen|tamoxifen]] are subtler.

== Inducers ==
CYP2D6 is essentially '''non-inducible''' by the classical PXR/CAR-mediated induction pathway. Rifampin, carbamazepine, phenobarbital, and St John's Wort, all potent inducers of CYP3A4 and other CYPs, have negligible effect on CYP2D6 expression. This is clinically important because it means CYP2D6-substrate dosing cannot be rescued by pharmacological induction; if a medicine fails because of CYP2D6 inhibition or because the patient is a poor metabolizer, the answer is to switch the offending inhibitor or switch to an alternative substrate, not to wait for tolerance to develop.

== Clinical implications, summary ==
For any medicine that depends materially on CYP2D6 for activation or elimination:

* Known PM phenotype: avoid prodrugs that require CYP2D6 activation (no analgesia from codeine/tramadol); reduce starting dose of substrates eliminated by CYP2D6 (typically 50% reduction for tricyclic antidepressants).
* Known UM phenotype: avoid codeine, tramadol, and other CYP2D6-activated prodrugs (toxicity risk from rapid morphine generation); standard or slightly increased dosing for substrates eliminated by CYP2D6.
* Standard genotype + strong CYP2D6 inhibitor co-prescribed: treat as phenocopy intermediate or poor metabolizer for the duration of the inhibitor's effect. Note that fluoxetine's effect persists 4–6 weeks beyond discontinuation because of norfluoxetine (half-life 7–15 days), and paroxetine's mechanism-based inhibition recovers over the synthesis half-life of CYP2D6 (~24–48 hours per enzyme copy) rather than over paroxetine's elimination half-life.

CPIC publishes phenotype-specific dosing guidance for codeine/tramadol, atomoxetine, ondansetron and tropisetron, several tricyclic antidepressants, several SSRIs, tamoxifen, pimozide, and others; the full set is maintained at clinpgx.org.<ref name="cpic-opioid-2021" /><ref name="caudle2020" />

== See also ==
* [[Phenotype:CYP2D6 poor metabolizer]]
* [[Phenotype:CYP2D6 intermediate metabolizer]]
* [[Phenotype:CYP2D6 normal metabolizer]]
* [[Phenotype:CYP2D6 ultrarapid metabolizer]]
* [[Enzyme:CYP3A4]], [[Enzyme:CYP2C19]], [[Enzyme:CYP2C9]]
* [[Codeine]], [[Tramadol]], [[Tamoxifen]], [[Fluoxetine]], [[Paroxetine]] (canonical clinical examples)

== References ==

<references/>

[[Category:Drug-metabolizing enzymes]]
[[Category:Pharmacogenomics]]

Enzyme:CYP2D6 - Revision history

MDElliottMD: Add scope="col" to the data-table column headers for screen-reader association (ADA audit M5; designer-claude 2026-05-22)

MDElliottMD: MDElliottMD moved page Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2D6 to Enzyme:CYP2D6: Migrate enzyme entity pages from Pharmacogenomics sandbox to the new Enzyme: namespace